| Gene symbol | KRAS | Synonyms | C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | KRAS proto-oncogene, GTPase | ||||
| GTO ID | GTC3930 |
| Trial ID | NCT06484790 |
| Disease | Solid Tumor |
| Altered gene | KRAS |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | NW-301V|NW-301D |
| HLA | HLA-A*11:01 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Open-label, Single-arm, Phase 1 Clinical Trial to Evaluate the Safety and Efficacy of Autologous TCR-T Cell Therapy in Subjects With Advanced Solid Tumors |
| Year | 2024 |
| Country | China |
| Company sponsor | Ting Deng |
| Other ID(s) | NW-301-001 |
| Cohort1: KRAS G12V mutation | |||||||||
|
|||||||||
| Cohort2: KRAS G12D mutation | |||||||||
|
|||||||||